• O-GlcNAcylation Drives Wnt-Induced Glycolysis in Bone Format

  2026-06-13

  This study uncovers how O-GlcNAcylation serves as a key mediator of Wnt3a-induced bone formation by rewiring aerobic glycolysis in osteoblasts. The findings reveal a dual mechanism for O-GlcNAcylation activation and identify its indispensability for osteogenesis, offering new insights for metabolic and signaling pathway research in bone biology.

• Nebivolol Hydrochloride: Selectivity, Assay Design, and mTOR

  2026-06-12

  Explore Nebivolol hydrochloride as a highly selective β1-adrenoceptor antagonist for cardiovascular and signaling research. This article reveals new experimental considerations, recent mTOR pathway findings, and advanced assay design strategies beyond typical applications.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Inhibition Wo

  2026-06-12

  Masitinib (AB1010) addresses the need for precise inhibition of the KIT, PDGFRα, and PDGFRβ tyrosine kinases in cancer biology, mastocytosis, and inflammation model systems. It is best suited for DMSO-based workflows where selective kinase targeting is required and should not be used in protocols that depend on broad-spectrum inhibition or require aqueous/ethanol solubility.

• Imatinib Hydrochloride: Optimized Workflows for Kinase Inhib

  2026-06-11

  Imatinib hydrochloride enables precise, multi-target kinase inhibition for advanced cancer research, from CML to GISTs. This article details experimental best practices, protocol optimization, and troubleshooting tips, leveraging both emerging mechanistic insights and APExBIO’s high-purity reagent standards.

• Epigenetic Modulation Shapes Immune Signatures in Melanoma

  2026-06-11

  Anichini et al. (2022) systematically profiled immune-related gene signatures induced by different classes of epigenetic regulators in melanoma, finding that the DNMT inhibitor guadecitabine uniquely enhances immune activation programs with clinical relevance. Their findings clarify the molecular rationale for combining specific epigenetic drugs with immunotherapy, offering new directions for translational cancer research.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Eviden

  2026-06-10

  A recent open-access study demonstrates that intravesical delivery of p21 mRNA–loaded lipid nanoparticles (LNPs) can restore tumor suppressor function and suppress tumor growth in non–muscle-invasive bladder cancer. This approach leverages localized mRNA therapy to overcome limitations of standard treatments, with strong mechanistic and preclinical support for clinical translation.

• Drug-Sensitized Yeast as a Sensitive Platform for mTOR Inhib

  2026-06-10

  The referenced study establishes a drug-sensitized yeast system to dramatically enhance the detection sensitivity for TOR/mTOR inhibitors, enabling identification of both established and novel compounds with TOR pathway activity. This approach offers a rapid, cost-effective means to screen for geroprotective or anti-cancer agents targeting mTOR, while also clarifying compound specificity for researchers.

• Tofacitinib Citrate: Applied Strategies in Immune Regulation

  2026-06-09

  Tofacitinib citrate (CP-690550 citrate) empowers researchers to dissect JAK-STAT pathway dynamics and endothelial inflammation with exceptional selectivity. Discover protocol-driven insights, troubleshooting strategies, and how recent vascular studies guide experimental design for immune and inflammatory models.

• Afatinib (BIBW 2992) in Advanced Gastric Cancer Assembloid M

  2026-06-09

  Harnessing Afatinib’s irreversible ErbB kinase inhibition, researchers can dissect drug response and resistance in physiologically relevant gastric cancer assembloids. This article provides actionable protocol enhancements, troubleshooting, and workflow tips to maximize the translational value of Afatinib (BIBW 2992) in next-generation cancer biology research.

• LGK-974 (Porcupine Inhibitor): Reliable Solutions for Wnt Pa

  2026-06-08

  This article provides practical, evidence-based guidance for biomedical researchers seeking robust and reproducible Wnt pathway inhibition using LGK-974 (Porcupine Inhibitor), SKU B2307. Drawing on validated protocols and recent literature, we address key challenges in experimental design, data interpretation, and product selection—demonstrating why APExBIO’s LGK-974 is a trusted resource for sensitive cell-based assays and Wnt-driven cancer models.

• Patient-Derived Gastric Cancer Assembloids Reveal Stromal Mo

  2026-06-08

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, enabling unprecedented investigation into the tumor microenvironment. The model enhances physiological relevance for preclinical research, reveals stromal-driven drug resistance, and supports more predictive, personalized therapy strategies.

• circRHOBTB3 Suppresses Prostate Cancer Metastasis via NONO-M

  2026-06-07

  This study uncovers circRHOBTB3 as a tumor suppressor that inhibits prostate cancer proliferation and metastasis by sequestering NONO in the cytoplasm and downregulating MAOA expression. These findings highlight a novel circRNA-mediated regulatory axis, suggesting circRHOBTB3 as a promising biomarker and therapeutic target in metastatic prostate cancer.

• Pravastatin Sodium: Applied Workflows for HMG-CoA Reductase

  2026-06-06

  Pravastatin sodium stands out as a selective HMG-CoA reductase inhibitor, enabling precise cholesterol biosynthesis inhibition and advanced cardiovascular research. This article unpacks translational protocols, troubleshooting guidance, and the latest insights on transporter dynamics to help researchers maximize data quality and reproducibility.

• Anlotinib Hydrochloride: Translating Multi-Kinase Inhibition

  2026-06-05

  Explore how Anlotinib hydrochloride, a leading multi-target tyrosine kinase inhibitor, enables next-generation, artifact-resistant angiogenesis and proliferation assays. This article uniquely connects pharmacokinetic depth, practical workflow optimization, and clinical context for advanced cancer research.

• Masitinib (AB1010): Technical Use in KIT/PDGFR Research

  2026-06-05

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor for precise inhibition of KIT, PDGFRα, and PDGFRβ, enabling reliable modeling of KIT-driven signaling in cancer, mastocytosis, and inflammatory disease research. It is not suitable for workflows requiring broad-spectrum kinase inhibition or aqueous/ethanol-based systems, and should be handled following strict solubility and storage protocols.

15197 records 1/1014 page Next 12345 下5页 Last page